OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

OptimizeRx Corp. (NASDAQ:OPRX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eleven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $10.81.

A number of equities analysts have recently issued reports on OPRX shares. Citigroup reaffirmed an "outperform" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Wall Street Zen upgraded OptimizeRx from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. B. Riley reissued a "buy" rating on shares of OptimizeRx in a report on Tuesday, May 13th. Roth Capital restated a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Finally, Stifel Nicolaus upped their price objective on shares of OptimizeRx from $12.50 to $16.00 and gave the company a "buy" rating in a report on Monday, June 9th.

OptimizeRx Stock Down 1.0%

OPRX traded down $0.14 on Friday, hitting $13.50. The company had a trading volume of 583,838 shares, compared to its average volume of 300,564. The stock has a market capitalization of $249.75 million, a price-to-earnings ratio of -16.07, a P/E/G ratio of 4.55 and a beta of 1.33. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.82 and a current ratio of 2.82. The stock has a fifty day moving average price of $11.79 and a 200-day moving average price of $8.22. OptimizeRx has a 12-month low of $3.78 and a 12-month high of $15.71.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported $0.08 earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.19. OptimizeRx had a negative net margin of 16.33% and a negative return on equity of 0.29%. The business had revenue of $21.93 million for the quarter, compared to analysts' expectations of $18.69 million. Analysts predict that OptimizeRx will post -0.33 EPS for the current fiscal year.

Hedge Funds Weigh In On OptimizeRx

Institutional investors have recently bought and sold shares of the business. SBI Securities Co. Ltd. purchased a new stake in shares of OptimizeRx in the 4th quarter valued at $25,000. GAMMA Investing LLC acquired a new position in OptimizeRx during the first quarter valued at $33,000. Wells Fargo & Company MN boosted its holdings in OptimizeRx by 33.3% in the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock valued at $54,000 after purchasing an additional 2,797 shares during the last quarter. Graham Capital Management L.P. acquired a new stake in OptimizeRx during the 4th quarter worth about $81,000. Finally, MetLife Investment Management LLC acquired a new stake in OptimizeRx during the 1st quarter worth about $99,000. 76.47% of the stock is owned by hedge funds and other institutional investors.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.